Integration of Artificial Intelligence and Microfluidics for Drug Delivery Applications
Abstract
The development of drug delivery systems (DDSs) is moving from empirical, trial-and-error formulation toward data-driven, artificial intelligence (AI)-guided, and automated workflows. Microfluidics provides precise control of microscale fluids, enabling high-throughput production of relatively homogeneous drug carriers such as liposomes, lipid nanoparticles (LNPs), and polymeric micelles. However, the high-dimensional parameter space of microfluidic reactors often exceeds the capacity of manual optimization. This review examines the integration of AI, particularly machine learning (ML), deep learning (DL), and Bayesian optimization, into microfluidic platforms for accelerating DDS design, optimizing critical quality attributes (CQAs), and supporting self-driving laboratory workflows. We discuss the technical foundations of AI-enabled microfluidics, applications in nanocarrier synthesis and phenotypic screening, and the evolving regulatory landscape for AI-assisted pharmaceutical development.
Read the paper
Related studies
- Learning from First-Generation Qualitative Approaches in the IS Discipline: An Evolutionary View and Some Implications for Authors and Evaluators (PART 1/2)
- Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models
- Prosthesis: New Technological Opportunities and Innovative Biomedical Devices
- The history and future of neural modeling for cochlear implants
- Ryanodine receptors: waking up from refractoriness
- Novel Transgenic Rabbit Model Sheds Light on the Puzzling Role of Matrix Metalloproteinase-12 in Atherosclerosis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.